<DOC>
	<DOCNO>NCT01038648</DOCNO>
	<brief_summary>The hypothesis , subject persistent impaired glucose tolerance ( IGT ) , sitagliptin decrease conversion rate diabetes compare placebo three year .</brief_summary>
	<brief_title>Sitagliptin Prevention Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>The DPP-4 inhibitor Sitagliptin may suitable preventive agent subject IGT IFG account observe functional improvement islet cell function potential protective effect beta cell mass . Objectives study 1 . Primary objective : - To test whether DPP4 inhibitor Sitagliptin effective prevent conversion IGT diabetes compare placebo . 2 . Secondary objective : - To assess rate reversal IGT Normal Glucose Tolerance ( NGT ) IGT patient administer Sitagliptin - To assess effect Sitagliptin measure beta cell function insulin resistance patient IGT . Study design Double blind placebo control , parallel group study - three year follow . Subjects IGT age group 30-55 year ( n=900 ) identify screen standard OGTT . Selected subject randomize control arm use placebo two study arm use Sitagliptin . At baseline group receive standard advice lifestyle modification . The dose sitagliptin 100 mg/d . The subject review 6 monthly interval repeat OGTT do annually . Proforma contain detail anthropometry , occupation , physical activity , diet habit , detail medication , regularity treatment biochemical investigation fill interview . Investigations : Initial Screening 1 . Demographic data 2 . Height , weight , waist hip measurement . 3 . Details family history diabetes , hypertension cardiovascular disease . 4 . History major illness . 5 . History blood pressure measurement . 6 . Details education occupation . 7 . Diet habit analyze dietician . 8 . Details physical activity assess questionnaire . Laboratory investigation : 1 . Initial OGTT 2 . Plasma glucose HbA1c . 3 . Lipid profile 4 . Liver function test 5 . Serum amylase serum lipase 6 . Plasma insulin 7 . 12 lead ECG . Review analysis : 1. Review do clinical biochemical assessment annually . 2 . Evaluation adherence prescription do 6 monthly interval .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Subjects IGT age group 3055 year ( n=900 ) identify screen standard OGTT . 1 . Known diabetes 2 . Pregnant woman 3 . Alcohol abuse 4 . Transferable job . 5 . Subjects major illness like cancer , hepatic cardiac disease .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Sitagliptin</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Prevention type 2 diabetes</keyword>
</DOC>